Journals / Güncel Retina Dergisi / 2021 / Cilt: 5 - Sayı: 2

Retinal Transplantation, Stem Cell and Gene Therapy in Retinitis Pigmentosa

Retinitis Pigmentosada Retina Transplantasyonu, Kök Hücre ve Gen Tedavisi

Pages
131–139
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review summarizes the clinical development of retinal stem cell and gene therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinitis pigmentosa is the most common hereditary retinal dystrophy which has marked clinical and genetic heterogeneity.
📊
Key Findings & Data:The known causative disease genes have a variety of developmental and functional roles, with mutations in more than 120 genes shown to be responsible for the phenotypes.
💡
Conclusion & Impact:This review summarizes the clinical development of retinal stem cell and gene therapy.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinitis pigmentosa is the most common hereditary retinal dystrophy which has marked clinical and genetic heterogeneity. Common presentations among this disorder include night blindness, tunnel vision, and subsequent progression to complete blindness respectively. The known causative disease genes have a variety of developmental and functional roles, with mutations in more than 120 genes shown to be responsible for the phenotypes. In addition, mutations within the same gene have been shown to cause different disease phenotypes, even within the same family, highlighting further levels of complexity. In recent years significant advancements have been made in the understanding of the pathogenesis of the disease and stem cell and gene replacement treatments have been proposed as potentially efficacious therapies. This review summarizes the clinical development of retinal stem cell and gene therapy.

Özet

Retinitis pigmentosa, herediter retina distrofileri içinde en sık görülenidir. Kliniği ve genetik geçişi oldukça çeşitlilik gösterir. Hastalığın semptomları sırayla gece körlüğü, tünel görme ve takiben tamamen körlük oluşumu şeklindedir. Neden olan genlerin gelişimsel ya da fonksiyonel işlevlerde görevleri vardır ve fenotipten sorumlu olan 120’den fazla gen mutasyonu bilinmektedir. Ayrıca aynı ailede, aynı gen içinde olan mutasyonların bile farklı fenotiplere yol açabildiği görülmekte; bu da genetik nedenlerin karmaşıklığını ortaya koymaktadır. Son yıllarda hastalığın patogenezinin anlaşılmasına yönelik gelişmeler, tedavide kök hücre ve gen tedavisi gibi etkin uygulamaların yapılmasını sağlamıştır. Bu derlemede kök hücre ve gen tedavilerinin klinik gelişimleri özetlenmiştir.

🔖

Cite This Article

ÖNER, A., KAHRAMAN, N. S. (2021). Retinal Transplantation, Stem Cell and Gene Therapy in Retinitis Pigmentosa. Güncel Retina Dergisi, Cilt: 5 - Sayı: 2, 131–139. https://ajindex.com/articles/219685

References (9)

  1. Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha Jr A, Woo SJ et al. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog. Retin. Eye Res. 2018;63:107-131. doi: 10.1016/ j.preteyeres. 2017.10.004. Shintani K, Shechtman DL, Gurwood AS. Review and update: Current treatment trends for patients with retinitis pigmentosa. Optometry 2009; 80(7): 384-401. Smith LE. Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa. J Clin Invest. 2004;114(6):755-7.
  2. Oner A, Gonen ZB, Sinim N, Cetin M, Ozkul Y. Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study. Stem Cell Res Ther. 2016;7(1):178. Oner A. Stem Cell Treatment in Retinal Diseases: Recent Developments. Turk J Ophthalmol. 2018; 48(1):33-38. Zarbin M. Cell-Based Therapy for Degenerative Retinal Disease. Trends Mol Med. 2016; 22(2): 115-34. Siqueira RC. Stem cell therapy for retinal diseases: update. Stem Cell Res Ther. 2011; 2(6): 50. Shintani K, Shechtman DL, Gurwood AS. Review and update: Current treatment trends for patients with retinitis pigmentosa. Optometry 2009; 80(7):384-401.
  3. Bennicelli J, Bennett J. Stem cells set their sights on retinitis pigmentosa. eLife 2013; 2:01291. Uy HS, Chan PS, Cruz FM. Stem Cell Therapy: a Novel Approach for Vision Restoration in Retinitis Pigmentosa. Med Hypothesis Discov Innov Ophthalmol. 2013; 2(2):52-55.
  4. Chung Y, Klimanskaya I, Becker S, Li T, Maserati M, Lu SJ, et al. Human embryonic stem cell lines generated without embryo destruction. Cell Stem Cell. 2008; 2(2): 113–117.
  5. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858): 1917–1920.
  6. Tucker BA, Mullins RF, Stone EM. Stem cells for investigation and treatment of inherited retinal disease. Human Molecular Genetics. 2014; 23: Review Issue 1 R9–R16 Bharti, K. Patching the retina with stem cells. Nat. Biotechnol. 2018; 36(4): 311–313.
  7. Tomita, M., Lavik, E., Klassen, H., Zahir, T., Langer, R., Young, M.J. Biodegradable polymer composite grafts promote the survival and differentiation of retinal progenitor cells. Stem Cells. 2005; 23(10): 1579–1588.
  8. Park SS, Moisseiev E, Bauer G, Anderson JD, Grant MB, Zam A, et al. Advances in bone marrow stem cell therapy for retinal dysfunction. Prog. Retin. Eye Res. 2017; 56: 148–165.
  9. Hirami Y, Os